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Abstract
Prostate cancer (PCa) is a major health issue in Westernized countries, representing a common cause of morbidity
and mortality in the elderly male population. Endogenous sex steroids, along with environmental factors (notably
diet) and host immune and inflammatory responses, are likely to cooperate in the pathogenesis of the disease.
Based on the assumption that a complex endocrine–inflammatory-immune interaction is primarily implicated in
human PCa, we have investigated the interplay between sex steroids and inflammation in development and
growth of human PCa. To this end, we have assessed nine functional single nucleotide polymorphisms (SNP)s of
five genes involved in sex hormone-related pathways in both hyperplastic and malignant human prostate tissues,
as well as in matched controls and in a ‘‘supercontrol’’ group composed of male Sicilian centenarians. In par-
ticular, the following genes were investigated: AR-OMIM313700, SRD5A2-NM-000348, CYP19-NM-031226,
ERS1-NM-001122742, ERS2-NM-001040276. A significant association with prostate cancer was found in seven out
of the nine SNPs considered. Although this is a preliminary study and larger investigations are needed to confirm
the role of these genes in PCa development and/or progression, our data might provide an experimental basis to
develop additional or alternative strategies for prevention and treatment of PCa.
Introduction
Sex steroid hormones are generally believed to play acritical role in the complex pathophysiology of human
PCa (Caruso et al., 2009; Ellem and Risbridger, 2010; Ricke
et al., 2007). Androgens are primarily responsible for devel-
opment and function of human prostate gland, as well as for
the maintenance of homeostasis of prostate tissues in the
adulthood. Themajor prostatic androgens are the testosterone
and its derivative dihydrotestosterone, produced locally
through the 5a-reductase enzyme. Most of their effects are
mediated by binding to androgen receptors (AR). Androgens
also represent well-established risk factors for development
and progression of benign and malignant disorders of pros-
tate gland (Ricke et al., 2007).
Today there is accumulating evidence suggesting that es-
trogens play a crucial role in both normal and diseased human
prostate (Carruba, 2007; Ellem and Risbridger, 2009, 2010;
McPherson et al., 2008). In particular, a combined action of
androgens and estrogens and their balance appear to be crit-
ically important in maintaining prostate health and tissue
homeostasis. An alteration of this balance has been recently
implicated in the development of both benign and malignant
diseases, including PCa (Ellem and Risbridger, 2009, 2010).
Aging men have unchanged or increased circulating levels
of estradiol, as opposed to the decline of plasmatic testoster-
one. Estrogen production is maintained through aromatiza-
tion of adrenal androgens driven by the aromatase enzyme,
especially in peripheral adipose tissue (Ellem and Risbridger,
2010). In normal prostate gland, the aromatase enzyme is
expressed within the stroma, while the malignant prostate
show an aberrant aromatase expression in the epithelial
compartment (Ellem and Risbridger, 2010). This withdraws
circulating testosterone and results in a significant reduction
of plasma testosterone to estradiol ratio that has been asso-
ciated to an increased risk of developing PCa (Carruba, 2007).
The estrogen role in human prostate is further compli-
cated by the differential expression and activity of the two
estrogen receptors (ER), a and b (Ellem and Risbridger, 2009,
2010). A sustained activation of ERa may eventually lead to
an aberrant proliferation, inflammation and to development
of premalignant lesions. In contrast, ERb appears to have
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antiproliferative effects and to exert a protective role against
prostate carcinogenesis (Ellem et al., 2009; Ellem and Ris-
bridger, 2009, 2010).
Despite the above evidence, many epidemiologic studies
have failed to show a significant association between circu-
lating sex steroids and prostate cancer risk (Crawford, 2009;
Plaza and Giovannucci, 2004). Undoubtedly, several issues
related to measurement of plasma steroids, both androgens
and estrogens, should be considered to explain this large in-
consistency of data. However, the ethnic variability and the
heterogeneity of genetic background among the individuals
may well have a major impact. In particular, single nucleotide
polymorphisms (SNPs) of genes involved in both metabolism
and action of steroid hormones may be primarily implicated.
An association between PCa risk and SNPs of genes whose
products are involved in sex hormone-related steroid path-
ways has been observed (Chae et al., 2009; Cussenot et al.,
2007; Dianat et al., 2009; Huhtaniemi et al., 2010; Mononen
and Schleutker, 2009).
Based on the hypothesis that both individual and combined
variations in genes that govern local bioavailability and action
of sex steroids canmodify the individual susceptibility to PCa,
we have investigated nine selected SNPs of five genes (AR-
OMIM313700, SRD5A2-NM 000348, CYP19-NM-031226,
ERS1-NM-001122742. ERS2-NM-001040276) involved in sex-
related hormone pathways, comparing subjects having hy-
perplastic and malignant prostate, healthy controls, and male
centenarians from Sicily. This latter represents a supercontrol
group, consisting of ‘‘exceptional individuals’’ who have been
able to escape major common age-related diseases, including
cancer (Cevenini et al., 2008; Imyanitov, 2009).
Subjects and Methods
Patients and controls
The study included 50 Sicilian patients having hyperplastic
(32%) and malignant prostate (68%) lesions recruited at the
time of diagnosis (age range: 60–80 years). Controls were 47
healthy male Sicilians according to their clinical history and
blood tests. A second control group consisted of 44 male
centenarians (>99 years), whose age was confirmed from re-
cords at the city hall and/or church registries. No cancer or
other age-related diseases were clinically detectable in the
centenarians, although some had reduced auditory and visual
acuity. Because immigration and intermarriage have histori-
cally been rare in the last hundred years, the ethnicity of all
participants was established by all four grandparents having
been born in Sicily. The study received approval from local
ethic committees and all participants gave their written in-
formed consent.
Genotyping
The study material consisted of DNA samples. The DNA
samples of both hyperplastic and cancer cases were obtained
from prostate tissue biopsies placed into a suitable volume of
RNA-later (RNA Stabilization Reagent, Applied Biosystems,
Foster City, CA, USA) to avoid RNA degradation. The DNA
samples of the two control groups were extracted from pe-
ripheral blood using salting out method (Miller et al., 1998).
Genomic DNA and total RNA were purified simultaneously
from each sample using an All-Prep DNA/RNA Mini Kit
(Qiagen, Dusseldorf, Germany). Samples were genotyped for
nine SNPs of the selected genes, as reported in bT1Table 1. For
genotyping, the procedure used was based on the Restriction
Fragment-Length Polymorphism-PCR (RFLP-PCR), cleavage
with specific restriction enzymes and separation of DNA
fragments by electrophoresis, as described in literature data.
Statistics
Allelic and genotypic frequencies were evaluated by gene
count. The datawere tested for the goodness of fit between the
observed and expected genotype frequencies, according to
Hardy-Weinberg equilibrium, by chi-square test. Significant
differences in frequencies among the three groups were cal-
culated by w2 (by 33, 32, and 22 tables, where appro-
priate).
Results
When comparing the genotype distribution and allele fre-
quencies of the nine SNPs selected in the three cohorts of
subjects, significant differences were observed for the follow-
ing SNPs: AR þ211G/A, SRD5A2 A49T, CYP19Arg264Cys,
CYP19 C1558T, ERS1 351A/G, ERS1 397T/C, ERS2 1082G/A
(see bT2Tables 2 and bT33, respectively).
As illustrated in the Table 2, significant differences were
found ( p¼ 0.01, by chi-square test, 33 table) in the genotype
distribution of AR þ211G/A SNP among the three groups.
Significant differences were also observed between patients
and matched controls ( p¼ 0.04), and between patients and
centenarians ( p¼ 0.03). In addition, a high frequency of the
AR þ211A allele expression was found in the three groups
( p¼ 0.0009 by chi-square test with Yates’s correction, 23
table), and in patients respect to matched controls and cen-
tenarians ( p¼ 0.005 and p¼ 0.003, respectively, by chi-square
test with Yates’s correction, 22 table) (Table 3).
Concerning the two SNPs (A49T and V89L) of the gene
encoding the 5a-reductase enzyme (SRD5A2), significant dif-
ferences were observed in genotype distribution of SRD5A2
A49T among the three groups ( p¼ 0.000008) (Table 2).
Significant differences were also revealed between patients
and matched controls ( p¼ 0.0003), and between patients and
centenarians ( p¼ 0.00003) (Table 2). Accordingly, an over-
expression of SRD5A2 49T allele was evidenced in the three
groups ( p¼ 0.0000009 by chi-square test with Yates’s correc-
tion, 23 table), and in patients with respect to both matched
controls and centenarians ( p¼ 0.0000001, by chi-square test
with Yates’s correction, 22 table) (Table 3).
Concerning the three SNPs selected of the aromatase-
CYP19 gene, significant differenceswere revealed in genotype
distribution of CYP19Arg264Cys among the three groups
( p¼ 0.01) (Table 2). A significant difference was also observed
between patients and centenarians ( p¼ 0.005 by chi-square
test, 32 table) (Table 2). As expected, an overexpression of
the CYP19-264Cys allele was observed among the three
groups ( p¼ 0.004 by chi-square test with Yates’s correction,
23 table) and in patients respect to centenarians ( p¼ 0.001
by chi-square test with Yates’s correction, 22 table) (Table 3).
Furthermore, the analysis revealed that the genotype distri-
bution of the CYP19-C1558T allele was significantly different
among three groups ( p¼ 0.003 by chi-square test, 33 table),
and between patients and centenarians ( p¼ 0.005 by chi-
square test, 32 table) (Table 2). Accordingly, the allele fre-
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quencies of CYP19 C1558T SNPwere significantly distributed
among three cohorts ( p¼ 0.007 by chi-square test with Yates’s
correction, 23 table) and between patients and centenarians
(0.001 by chi-square test with Yates’s correction, 22 table)
(Table 3). No significant differences both in the genotype
distribution and allele frequency of CYP19-39Trp/Arg among
the three cohorts were evidenced (data no shown).
As reported in Table 2, significant differences were also
obtained in genotype distributions and allele frequencies of
ERS1-351A/G and 397T/C SNPs. In particular, significant
differences were observed in the genotype distribution of
ERS1-351A/G among the three groups ( p¼ 0.001), between
patients and matched controls ( p¼ 0.03) and between pa-
tients and centenarians ( p¼ 0.0009). Accordingly, an over-
expression of the ERS1-351G allele was observed among the
three groups ( p¼ 0.0001 by chi-square test with Yates’s cor-
rection, 23 table), in patients with respect to centenarians
( p¼ 0.0002 by chi-square test with Yates’s correction, 22
table) and between patients and matched controls ( p¼ 0.006
by chi-square test with Yates’s correction, 22 table) (Table 3).
The genotype distribution of ERS1-397T/C was significantly
different among the three groups ( p¼ 0.01 by chi-square test,
33 table), and between patients and centenarians ( p¼ 0.005
by chi-square test, 32 table) (Table 2). Hence, the allele fre-
quencies were significantly distributed among three cohorts
( p¼ 0.004 by chi-square test with Yates’s correction, 23
table) and between patients and centenarians ( p¼ 0.001 by
chi-square test with Yates’s correction, 22 table) (Table 3).
Table 1. Genes (Accession Number), SNPs (Accession Number),
and Substitutions Investigated in the Study
Genes SNPs Biological effect
AR (OMIM313700) þ211G/A (G1733A), rs6152
A49T, rs9282858
Located within exon 1, the SNP consists in a G to A change
in the third position of codon 211. The A allele has associated
with a statistically significant nearly threefold increased risk
of PCa among African American men (age <65 years);
likewise, an excess proportion of this allele has been found
among PCa cases with an affected brother. European studies
have also observed an association between A allele and
high-grade disease.
SRD5A2
(NM000348)
V89L, rs523349 A49T SNP substitutes threonine for alanine at codon 49; the T
allele has been reported to be the allele with higher enzyme
activity. It has been associated with a higher risk of PCa.
C1558T, rs1062033 V89L SNP substitutes leucine for valine at codon 89; it has been
reported to reduce almost 30% of adrostanediol glucuronide,
a serum marker of 5-a-reductase activity among Asian.
Among Caucasian men, a 10% insignificantly lower
androstanediol glucuronide level has been observed in
individuals with the L/L genotype. Hence, V89L might
reduce the risk for PCa.
CYP19
(NM-031226)
39Trp/Arg, rs2236722
Arg264Cys, rs700519
It is a silent SNP in exon 10, corresponding to the 30
untranslated region of mRNA; it has been proposed as
functionally relevant, because it is correlated to level of
aromatase mRNA in tumor cells.
Located in the codon 39Trp/arg, it is significantly associated
with PCa.
Located in the exon 7, it determines the C to T substitution
in the position of nucleotide 826, resulting in the substitution
from Arg to CYs at codon 264. It has been associated with
an increased risk of PCa
ERa, ESR1 A351G, rs: 9340799
T397C, rs: 2234693
351A/G (or Xba I) and 397T/C (or PvuII), most widely studied
SNPs of ER1 gene, seem to be in linkage disequilibrium. They
have been associated with higher risk of prostate cancer.
Concerning the XbaI SNP, higher circulating levels of
androstenedione have been observed in A/A (or x/x
genotype) The polymorphism IVS1-397 was described as
a C-to-T change in the intron of estrogen receptor (located
at position 397 before exon 2; http://genome.ucsc.edu).
The substitution of T generates a sequence, which can
be cut by ESR1 IVS1-397 T/C (PvuII) (CAG/CTG—
complementary strand). This SNP has been associated
with estrogen-dependent diseases. The clinical data indicate
that carriage of this SNP has functional consequences
by influencing ESR ligand binding and local estrogenic
action
ERb, ESR2 G1082A, (no rs
available designation)
It has been reported to be associated with increased estrogen
dysfunction.
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Concerning the ERS2-1082G/A SNP, significant differ-
ences were also found in genotype distribution of among
the three groups ( p¼ 0.0001 by chi-square test, 33 table),
between patients and matched controls ( p¼ 0.001 by
chi-square test, 32 table) and between patients and cente-
narians ( p¼ 0.001 by chi-square test, 32 table). As a con-
sequence, ERS2 1082A allele was overexpressed among
the three groups ( p¼ 0.00005 by chi-square test with
Yates’s correction, 23 table), in patients respect to cente-
narians ( p¼ 0.001 by chi-square test with Yates’s correction,
22 table) and between patients and matched controls
( p¼ 0.006 by chi-square test with Yates’s correction, 22
table) (Table 3).
In our study the hyperplastic (16) and malignant (34) cases
were included in the same group, because the analysis of the
data in the separated cohorts (hyperplastic and malignant
cases) compared to two control groups did not demonstrate
any difference.
In summary, the alleles associated with increased PCa risk
were overrepresented in patients compared to healthy men
and to centenarians.
Discussion and Conclusion
The molecular pathology of PCa is intricate. Endogenous
sex steroids along with environmental factors (e.g., diet) and
Table 2. Genotype Distribution of SNPs of AR, SRD5A2, CYP19, ERS1, and ERS2 Genes in 50 Hyperplastic
and Malignat Cases, 47 Matched Controls, and 44 Centenarians
SNPs Genotypes
Cases
N %
Matched
controls N %
Centenarians
N %
P1a
(33 table)
P2b
(32 table)
P3c
(32 table)
þ211G/A-AR GG 39
78%
44
93.6%
42
95.4%
0.01 0.04 0.03
GA 6
12%
3
6.4%
2
4.6%
AA 5
10%
0
0%
0
0%
A49T- SRD5A2 A49A 21
42%
38
80%
37
84%
0.000008 0.0003 0.00003
A49T 11
22%
5
11%
6
14%
T49T 18
36%
4
9%
1
2%
Arg264Cys-CYP19 Arg264Arg 37
74%
41
87%
43
98%
0.01 NS 0.005
Arg264Cys 11
22%
6
13%
1
2%
Cys264Cys 2
4%
0
0%
0
0%
C1558T-CYP19 C1558C 35
70%
39
83%
42
95%
0.003 NS 0.005
C1558T 13
26%
7
15%
2
5%
T1558T 2
4%
1
2%
0
0%
351A/G-ERS1 351A/A 34
68%
42
89%
43
98%
0.001 0.03 0.0009
351A/G 13
26%
4
9%
1
2%
351G/G 3
6%
1
2%
0
0%
397T/C-ERS1 397T/T 37
74%
41
87%
43
98%
0.01 NS 0.005
397T/C 11
22%
6
13%
1
2%
397C/C 2
4%
0
0%
0
0%
1082G/A-ERS2 1082G/G 33
66%
45
96%
42
95%
0.0001 0.001 0.001
1082G/A 16
32%
2
4%
2
5%
1082A /A 1
2 %
0
0%
0
0%
All genotypes were in Hardy-Weinberg equilibrium.
P1a¼ significance values calculated by chi-square test, analyzing the data of these SNPs among the three groups.
P2b¼ significance values calculated by chi-square test, analyzing the data of these SNPs between patients and age-matched controls.
P3c¼ significance values calculated by chi-square test, analyzing the data of these SNPs between patients and centenarians.
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host immune and inflammatory responses are likely to co-
operate in the pathogenesis of this neoplastic disease (Caruso
et al., 2009; De Marzo et al., 2007).
Based on this assumption, we have analyzed the associa-
tion between PCa and nine functional SNPs of the AR,
SRD5A2, CYP19, ERS1 e ERS2 genes involved in sex hormone
pathways. Our results suggest the potential association of
seven out of nine SNPswith PCa. They also reveal thatmost of
the selected alleles are underrepresented in centenarians, used
in our study as an additional supercontrol group of ‘‘excep-
tional individuals’’ free of major common age-related dis-
eases, including cancer (Cevenini et al., 2008; Imyanitov,
2009).
Our data also imply that alleles associated with age-related
diseases, including PCa, are not prominent in the genetic
profile favouring longevity, as indicated in our previous
studies (Candore et al., 2007a, 2007b). Based on this evidence,
one could speculate that the genes selected in our study may
function in an antagonistically pleiotropic manner. They exert
a beneficial role in younger age maintaining growth and ho-
meostasis of the prostate gland, while they play a detrimental
role producing an aberrant cell proliferation, inflammation
and the development of premalignant and malignant lesions
later in life.
The mechanisms underpinning the putative role of the se-
lected alleles in the development and/or progression of PCa
during the aging process, however, remain unknown. Larger
studies are needed to confirm the findings of this preliminary
report and to get insights into relevant mechanisms, with
special emphasis on local metabolism and action of either
androgens or estrogens. It should be noted that circulating sex
steroids cannot be considered representative of their in-
traprostatic levels that strictly depends upon expression and
activity of key enzymes governing local metabolism and
biotransformation (Carruba, 2007). In this respect, the ap-
praisal of steroid enzymes (such as aromatase and 5-a re-
ductase) and receptors (such as AR, ERa and ERb), that
respectively determine metabolic profiles and signaling in
both normal and diseased human prostate, is crucially im-
portant to associate sex hormone-related pathways and PCa
risk. In this framework, our data, although preliminary, might
provide an important experimental basis to develop addi-
tional or alternative strategies for prevention and treatment of
human PCa.
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